Jesse Goodman - Gsk Plc Director

GSK
 Stock
  

USD 29.43  0.07  0.24%   

  Director
Dr. Jesse Goodman is NonExecutive Independent Director of the Company since 1 January 2017. Dr Jesse previously served in senior leadership positions at the US Food and Drug Administration, including most recently as the FDAs Chief Scientist and previously as Deputy Commissioner for Science and Public Health and as Director of the Center for Biologics Evaluation and Research . Jesse played a leadership role in developing the FDAs Regulatory Science and Medical Countermeasures Initiatives and has worked collaboratively with industry, academia, government and global public health and regulatory partners to prepare for and respond to major public health threats, including emerging infectious diseases, disasters and terrorism. He led the FDAs response to West Nile Virus and to the 2009 H1N1 influenza pandemic and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. Jesse brings scientific and public health expertise to the Boards deliberations. Jesse, currently Professor of Medicine at Georgetown University, directs the Georgetown University Center on Medical Product Access, Safety and Stewardship and is an active clinician who serves as Attending Physician in Infectious Diseases. He also serves as President and Member of the Board of the United States Pharmacopeia, a member of the Regulatory and Legal Working Group of the Coalition for Epidemic Preparedness Innovations and of the US National Academy of Medicine. Jesse is a member of the Board of Intellia Therapeutics, Cambridge, MA.
Age: 69  Director Since 2017  Ph.D    
44 20 8047 5000  https://www.gsk.com

Gsk Plc Management Efficiency

Gsk Plc ADR has Return on Asset of 6.58 % which means that on every $100 spent on asset, it made $6.58 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 24.71 %, implying that it generated $24.71 on every 100 dollars invested. Gsk Plc management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 22.11 B in debt with debt to equity (D/E) ratio of 0.98, which is OK given its current industry classification. Gsk Plc ADR has a current ratio of 1.4, which is typical for the industry and considered as normal. Debt can assist Gsk Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Gsk Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gsk Plc ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gsk Plc to invest in growth at high rates of return. When we think about Gsk Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

DIRECTOR Since

Alain MonieAmazon Inc
2008
Jamie GorelickAmazon Inc
2012
Indra NooyiAmazon Inc
2019
Tom AlbergAmazon Inc
2016
Wendell WeeksAmazon Inc
2016
Thomas RyderAmazon Inc
2011
William GordonAmazon Inc
2003
John BrownAmazon Inc
2004
Jonathan RubinsteinAmazon Inc
2010
Rosalind BrewerAmazon Inc
2019
Judith McGrathAmazon Inc
2014
Thomas AlbergAmazon Inc
2011
Patricia StonesiferAmazon Inc
2017
Daniel HuttenlocherAmazon Inc
2016
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States. Gsk Plc ADR (GSK) is traded on New York Stock Exchange in USA and employs 90,096 people.

Gsk Plc ADR Leadership Team

Elected by the shareholders, the Gsk Plc's board of directors comprises two types of representatives: Gsk Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gsk Plc. The board's role is to monitor Gsk Plc's management team and ensure that shareholders' interests are well served. Gsk Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gsk Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Harry Dietz, Non-Executive Independent Director, Scientific and Medical Expert
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Independent Director
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director
Bill Louv, Senior Vice President - Core Business Services
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Shobie Ramakrishnan, Chief Digital and Technology Officer
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Anne Beal, Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert
Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President, Group General Counsel, Legal and Compliance
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Tony Wood, Chief Scientific Officer - Designate
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital and Technology Officer
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources

Gsk Plc Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gsk Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Gsk Plc Implied Volatility

    
  33.2  
Gsk Plc's implied volatility exposes the market's sentiment of Gsk Plc ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gsk Plc's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gsk Plc stock will not fluctuate a lot when Gsk Plc's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gsk Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gsk Plc's short interest history, or implied volatility extrapolated from Gsk Plc options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Gsk Plc ADR using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running Gsk Plc ADR price analysis, check to measure Gsk Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gsk Plc is operating at the current time. Most of Gsk Plc's value examination focuses on studying past and present price action to predict the probability of Gsk Plc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Gsk Plc's price. Additionally, you may evaluate how the addition of Gsk Plc to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Gsk Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gsk Plc. If investors know Gsk Plc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gsk Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Gsk Plc ADR is measured differently than its book value, which is the value of Gsk Plc that is recorded on the company's balance sheet. Investors also form their own opinion of Gsk Plc's value that differs from its market value or its book value, called intrinsic value, which is Gsk Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gsk Plc's market value can be influenced by many factors that don't directly affect Gsk Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gsk Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Gsk Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gsk Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.